The Arrival of Economic Evidence in Managed Care Formulary Decisions
The Unsolicited Request Process
Bibliographic Data
| ID | 9103721 |
|---|---|
| Authors | Peter J Neumann (0000-0003-1226-4073, Harvard University, corresponding author) |
| Year | 2005 |
| Volume | 43 |
| Issue | 7 |
| Pages | II-27 |
| Publication date | 2005-07-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/01.mlr.0000170005.09751.b4 |
| PMID | 16056006 |
| OpenAlex | W2053033550 |
| Language | EN |
| Citations received | 3 |
| References cited | 13 |
Managed care plans have traditionally resisted using economic evidence explicitly in drug formulary decisions, even as they used ever more aggressive and sophisticated processes for managing care. In recent years, this has changed as health plans have begun to adopt evidence-based and value-based formulary submission guidelines. The guidelines have the potential to serve as a national unifying template for pharmacy and therapeutics committees to consider clinical and economic information in a systematic and rigorous fashion. However, many questions remain about their use and about the nature of communications (called "unsolicited requests") from plans to drug companies for information. This article describes the unsolicited request process and its potential impact on the use of economic evidence in formulary decisions
Business · Economic growth · Economics · Family medicine · Formulary · Health care · Managed care · Medical emergency · MEDLINE · Operations management · Political science · Health Systems, Economic Evaluations, Quality of Life · Healthcare Policy and Management · Medicine · Pharmaceutical Economics and Policy
| Citations per year | 0.14 |
|---|---|
| Citation span | 2005 - 2005 (1) |
| Highly cited | No |